



# AMD

## Age-related macular degeneration

# Czech Republic



"Despite the existing 37 centers, there is still need for new centers, mainly due to capacity limits of existing centers, low willingness to redistribute patients within region to centers with free capacities and uneven distribution of budgets among existing centers."

CEO of an international chain of ophthalmological clinics

### 2 types of AMD

**wet AMD**  
Treatment using Anti-VEGF drugs

**dry AMD**  
there is no treatment


<b>Lucentis</b>	<b>Eylea</b>	<b>Beovu</b>	<b>Avastin</b>
Health Insurance Fund + 4,6% copayment	Health Insurance Fund + 10,3% copayment	Health Insurance Fund + 13,3% copayment	Patients pay full price of treatment

### Reimbursement and co-payment of Anti-VEGF drugs

Anti-VEGF drug	Reimbursed by Health Insurance Fund	Copayment
Lucentis	16 258 CZK (651 EUR)	757 CZK (30 EUR)
Eylea	16 258 CZK (651 EUR)	1668 CZK (67 EUR)
Beovu	16 258 CZK (651 EUR)	2156 CZK (86 EUR)

Source: SUKL

### Unique AMD patients in VZP Health Insurance Company



Costs per unique patient is relatively stable over time and anchors around 67 000 CZK

Source: VZP, 2020

### Payment mechanism= Annual budget

The Anti-VEGF treatment is paid on an **annual budget principle**, where the budget from previous year serves as starting point. The center must contract each insurance fund separately. So, if there are 37 centers, and 7 HIFs, this makes **259 contracts** for the whole Czech Republic.



**37 specialized centers**  
**Insufficient**

I have health insurance

I do not have health insurance

Treatment	Reimbursement by Health Insurance Fund	Copayment	Self-payers
Initial examination for both eyes	Fully reimbursed	-	4 900 CZK
OCT angiography	-	650 CZK/ eye	650 CZK/eye
Intraocular injection	Fully reimbursed	-	17 568 CZK/eye
Applied drug	Reimbursed	757-2157 CZK	included in the line above
Genetic test to assess risk of AMD	-	2 500 CZK	2 500 CZK

Source: own compilation based on HIF data, SUKL, expert interviews and Lexum



### Good practice

- Each injection paid separately by HIF
- The biological treatment anti- VEGF can be applied only in a specialized centre



### Room for improvement

- To increase the capacity or number of specialized centres
- To enforce Avastin to be used as "Off-label" indication

### Access to healthcare services in the context of financing mechanisms. The case of ophthalmology



Start: 01-11-2021  
 End: 30-04-2023  
 Project ID: N22120107  
 Programme: Visegrad Fund